Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

Delirium (PDQ®): Supportive care - Health Professional Information [NCI] - General Management Approach to Delirium


General information about clinical trials is also available from the NCI Web site.


  1. Breitbart W, Chochinov HM, Passik S: Psychiatric aspects of palliative care. In: Doyle D, Hanks GW, MacDonald N, eds.: Oxford Textbook of Palliative Medicine. 2nd ed. New York, NY: Oxford University Press, 1998, pp 933-56.
  2. Lawlor PG, Fainsinger RL, Bruera ED: Delirium at the end of life: critical issues in clinical practice and research. JAMA 284 (19): 2427-9, 2000.
  3. Gagnon P, Charbonneau C, Allard P, et al.: Delirium in advanced cancer: a psychoeducational intervention for family caregivers. J Palliat Care 18 (4): 253-61, 2002 Winter.
  4. Lawlor PG, Bruera ED: Delirium in patients with advanced cancer. Hematol Oncol Clin North Am 16 (3): 701-14, 2002.
  5. McCusker J, Cole M, Abrahamowicz M, et al.: Environmental risk factors for delirium in hospitalized older people. J Am Geriatr Soc 49 (10): 1327-34, 2001.
  6. Meagher DJ, O'Hanlon D, O'Mahony E, et al.: The use of environmental strategies and psychotropic medication in the management of delirium. Br J Psychiatry 168 (4): 512-5, 1996.
  7. Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry 156 (5 Suppl): 1-20, 1999.
  8. Gaudreau JD, Gagnon P, Harel F, et al.: Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 23 (27): 6712-8, 2005.
  9. Lawlor PG, Gagnon B, Mancini IL, et al.: Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 160 (6): 786-94, 2000.
  10. Sagawa R, Akechi T, Okuyama T, et al.: Etiologies of delirium and their relationship to reversibility and motor subtype in cancer patients. Jpn J Clin Oncol 39 (3): 175-82, 2009.
  11. Lawlor PG: The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer 94 (6): 1836-53, 2002.
  12. Gaudreau JD, Gagnon P, Roy MA, et al.: Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 109 (11): 2365-73, 2007.
  13. Morita T, Tei Y, Tsunoda J, et al.: Increased plasma morphine metabolites in terminally ill cancer patients with delirium: an intra-individual comparison. J Pain Symptom Manage 23 (2): 107-13, 2002.
  14. Lawlor PG: Delirium and dehydration: some fluid for thought? Support Care Cancer 10 (6): 445-54, 2002.
  15. Adityanjee, Schulz SC: Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 63 (Suppl 13): 32-8, 2002.
  16. Tune L: The role of antipsychotics in treating delirium. Curr Psychiatry Rep 4 (3): 209-12, 2002.
  17. Breitbart W, Tremblay A, Gibson C: An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 43 (3): 175-82, 2002 May-Jun.
  18. Breitbart W, Marotta R, Platt MM, et al.: A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153 (2): 231-7, 1996.
  19. US Food and Drug Administration.: FDA Alert (September 17, 2007): Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). Rockville, Md: Food and Drug Administration, Center for Drug Evaluation and Research, 2007. Available online. Last accessed January 18, 2013.
  20. Hassaballa HA, Balk RA: Torsade de pointes associated with the administration of intravenous haloperidol. Am J Ther 10 (1): 58-60, 2003 Jan-Feb.
  21. Khojainova N, Santiago-Palma J, Kornick C, et al.: Olanzapine in the management of cancer pain. J Pain Symptom Manage 23 (4): 346-50, 2002.
  22. Kim SW, Yoo JA, Lee SY, et al.: Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol 25 (4): 298-302, 2010.
  23. Kim KY, Bader GM, Kotlyar V, et al.: Treatment of delirium in older adults with quetiapine. J Geriatr Psychiatry Neurol 16 (1): 29-31, 2003.
  24. Boettger S, Friedlander M, Breitbart W, et al.: Aripiprazole and haloperidol in the treatment of delirium. Aust N Z J Psychiatry 45 (6): 477-82, 2011.
  25. Morita T, Otani H, Tsunoda J, et al.: Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer 8 (2): 134-7, 2000.
  26. Platt MM, Breitbart W, Smith M, et al.: Efficacy of neuroleptics for hypoactive delirium. J Neuropsychiatry Clin Neurosci 6 (1): 66-7, 1994 Winter.
  27. Gagnon B, Low G, Schreier G: Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 30 (2): 100-7, 2005.
  28. Fainsinger RL, Tapper M, Bruera E: A perspective on the management of delirium in terminally ill patients on a palliative care unit. J Palliat Care 9 (3): 4-8, 1993 Autumn.
  29. Caraceni A: Delirium in palliative medicine. European Journal of Palliative Care 2 (2): 62-7, 1995.
  30. MacLeod AD: The management of delirium in hospice practice. European Journal of Palliative Care 4 (4): 116-20, 1997.
  31. Bergevin P, Bergevin RM: Recognizing delirium in terminal patients. Am J Hosp Palliat Care 13 (2): 28-9, 1996 Mar-Apr.
  32. Twycross RG: Symptom control: The problem areas. Palliat Med 7 (Suppl 1): 1-8, 1993.
  33. Rietjens JA, van Zuylen L, van Veluw H, et al.: Palliative sedation in a specialized unit for acute palliative care in a cancer hospital: comparing patients dying with and without palliative sedation. J Pain Symptom Manage 36 (3): 228-34, 2008.
  34. Cherny NI, Portenoy RK: Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 10 (2): 31-8, 1994 Summer.
  35. Macleod AD: Use of sedatives in palliative medicine. Palliat Med 11 (6): 493-4, 1997.
  36. Morita T, Tsuneto S, Shima Y: Definition of sedation for symptom relief: a systematic literature review and a proposal of operational criteria. J Pain Symptom Manage 24 (4): 447-53, 2002.
  37. Fainsinger RL: Treatment of delirium at the end of life: Medical and ethical issues. In: Portenoy RK, Bruera E, eds.: Topics in Palliative Care. Volume 4. New York, NY: Oxford University Press, 2000, pp 261-77.
  38. Fainsinger RL, Waller A, Bercovici M, et al.: A multicentre international study of sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 14 (4): 257-65, 2000.
  39. Morita T, Chinone Y, Ikenaga M, et al.: Ethical validity of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage 30 (4): 308-19, 2005.
  40. Morita T, Chinone Y, Ikenaga M, et al.: Efficacy and safety of palliative sedation therapy: a multicenter, prospective, observational study conducted on specialized palliative care units in Japan. J Pain Symptom Manage 30 (4): 320-8, 2005.
  41. Chater S, Viola R, Paterson J, et al.: Sedation for intractable distress in the dying--a survey of experts. Palliat Med 12 (4): 255-69, 1998.
  42. Fainsinger RL, Landman W, Hoskings M, et al.: Sedation for uncontrolled symptoms in a South African hospice. J Pain Symptom Manage 16 (3): 145-52, 1998.
  43. Fainsinger RL, De Moissac D, Mancini I, et al.: Sedation for delirium and other symptoms in terminally ill patients in Edmonton. J Palliat Care 16 (2): 5-10, 2000 Summer.
  44. Elsayem A, Curry Iii E, Boohene J, et al.: Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center. Support Care Cancer 17 (1): 53-9, 2009.
  45. Caraceni A, Zecca E, Martini C, et al.: Palliative sedation at the end of life at a tertiary cancer center. Support Care Cancer 20 (6): 1299-307, 2012.
  46. Fainsinger RL, Bruera E: Is this opioid analgesic tolerance? J Pain Symptom Manage 10 (7): 573-7, 1995.
  47. Fainsinger RL: Use of sedation by a hospital palliative care support team. J Palliat Care 14 (1): 51-4, 1998 Spring.
  48. de Stoutz ND, Tapper M, Fainsinger RL: Reversible delirium in terminally ill patients. J Pain Symptom Manage 10 (3): 249-53, 1995.
  49. Dunlop RJ: Is terminal restlessness sometimes drug induced? Palliat Med 3: 65-6, 1989.
  50. Rousseau PC: Palliative sedation. Am J Hosp Palliat Care 19 (5): 295-7, 2002 Sep-Oct.
  51. Cowan JD, Palmer TW: Practical guide to palliative sedation. Curr Oncol Rep 4 (3): 242-9, 2002.
  52. Ashby M: Palliative care, death causation, public policy and the law. Progress in Palliative Care 6 (3): 69-77, 1998.
  53. Cherny NI: Commentary: sedation in response to refractory existential distress: walking the fine line. J Pain Symptom Manage 16 (6): 404-6, 1998.
  54. Rosen EJ: Commentary: a case of "terminal sedation" in the family. J Pain Symptom Manage 16 (6): 406-7, 1998.
  55. van Dooren S, van Veluw HT, van Zuylen L, et al.: Exploration of concerns of relatives during continuous palliative sedation of their family members with cancer. J Pain Symptom Manage 38 (3): 452-9, 2009.

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

Building a Support System
cancer fighting foods
precancerous lesions slideshow
quit smoking tips
Jennifer Goodman Linn self-portrait
what is your cancer risk
colorectal cancer treatment advances
breast cancer overview slideshow
prostate cancer overview
lung cancer overview slideshow
ovarian cancer overview slideshow
Actor Michael Douglas